RLM.L Regulatory News (RLM)

13 Nov 2006 07:02

PuriCore Plc13 November 2006 PuriCore Appointment Andrea Holtzman Drucker named as General Counsel and Corporate Secretary Malvern, Pennsylvania, and Stafford, UK, 13 November 2006 -- PuriCore plc("PuriCore") (London Stock Exchange: PURI), the developer of a novel, safetechnology that mimics the human body's natural anti-microbial, hypochlorousacid, today announces that the company has appointed attorney Andrea ("Andi")Holtzman Drucker as Senior Vice President, General Counsel, and CorporateSecretary effective immediately. Ms. Drucker joins PuriCore from Novavax, Inc., a publicly traded vaccinecompany, where she has been acting General Counsel since December 2005. Ms.Drucker previously served as interim Associate General Counsel at publiclylisted Auxilium Pharmaceuticals, Inc. At both companies Ms. Drucker wasresponsible for commercial transactions focusing on business development, aswell as corporate governance, intellectual property and regulatory mattersassociated with the U.S. Food and Drug Administration. Prior to joining Auxilium, Ms. Drucker spent 17 years at FMC Corporation in anumber of roles including six years as Group Counsel of FMC BioPolymer, aglobal performance chemicals business providing ingredients and excipients tothe pharmaceutical industry. A graduate of Cornell University and theUniversity of Pennsylvania School of Law, Ms. Drucker began her career as anattorney with the Philadelphia law firm Ballard Spahr Andrews & Ingersoll. Greg Bosch, the Chief Executive of PuriCore, commented: "I am delighted that Andi is joining the PuriCore management team. With herbackground in life sciences at both large, well-established and smallerorganizations, she brings invaluable experience that will add tremendous valueto PuriCore's current and developing businesses." FOR FURTHER INFORMATION: PuriCore plc Tel: +1 (484) 321-2701Greg Bosch, Chief Executive OfficerKeith A. Goldan, Chief Financial Officer Financial Dynamics Tel: +44 (0) 20 7831 3113Ben BrewertonJohn Gilbert ABOUT PURICORE PLC PuriCore is a life sciences company focused on the development andcommercialization of its proprietary technology that mimics the production bythe human body of its natural anti-microbial, hypochlorous acid. Hypochlorousacid is highly effective at killing pathogens such as bacteria, viruses andfungi and yet is safe and environmentally friendly. PuriCore's solutions haveapplications in a wide range of markets where it is important to controlmicrobial contamination. These markets include medical device disinfection,food safety, dental equipment decontamination, environmental remediation,hospitality, water safety, wound management and other applications intended tolimit the spread of infectious disease, including major global threats such asTuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis A,H.pylori and Legionella. PuriCore markets a portfolio of branded systems which produce hypochlorous acidsolutions on-site at a customer's location from water, electricity and commonsalt. These solutions are generated at a range of concentrations and at anearly neutral pH range similar to the human body. They are effective as soaks,sprays, mists and in other forms. PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford,UK. To receive additional information on the Company, please visit our Web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange